{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:11:25Z","timestamp":1790381485955,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Acute enteral baclofen withdrawal can be clinically severe if not identified and managed appropriately. Treatment of baclofen withdrawal includes supportive care and reinitiation of baclofen. There are limited pharmacotherapeutic interventions available to manage symptoms of acute enteral baclofen withdrawal, especially in nonintubated patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>We describe a 61-year-old Caucasian male with a past medical history of chronic back pain and spinal stenosis who was admitted to the medical intensive care unit with confusion, insomnia, agitation, delirium, and auditory and visual hallucinations. For control of agitation, the patient was administered 10 mg of i.v. haloperidol, 1 mg of i.v. lorazepam, and 14 mg of i.v. midazolam, with minimal improvement noted; therefore, dexmedetomidine was initiated, which led to clinical resolution of his symptoms. Upon further investigation it was determined that the patient was taking approximately 10 baclofen 20-mg tablets a day. According to his pharmacy records, he had filled prescriptions for a total of 738 baclofen tablets in the previous 12 weeks. The patient\u2019s presentation and sudden discontinuation of high-dose baclofen led to a diagnosis of baclofen withdrawal. Baclofen was subsequently restarted, and dexmedetomidine was weaned over 36 hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Dexmedetomidine controlled this patient\u2019s agitation and delirium without suppressing his respiratory drive and should be considered for management of acute enteral baclofen withdrawal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz332","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T01:16:25Z","timestamp":1578878185000},"page":"352-355","source":"Crossref","is-referenced-by-count":8,"title":["Enteral baclofen withdrawal managed with intravenous dexmedetomidine: A case report"],"prefix":"10.1093","volume":"77","author":[{"given":"Aubrey","family":"Defayette","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Perrello","sequence":"first","affiliation":[{"name":"Kaleida Health, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brewer","sequence":"first","affiliation":[{"name":"Kaleida Health, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Picano","sequence":"first","affiliation":[{"name":"University at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmed","sequence":"first","affiliation":[{"name":"Baylor University Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"2020021903593955400_CIT0001","volume-title":"Gablofen [package insert]","year":"2017"},{"key":"2020021903593955400_CIT0002","first-page":"781","article-title":"Medication withdrawal in the intensive care unit.","volume-title":"Critical Care Pharmacotherapy","author":"Sloan"},{"key":"2020021903593955400_CIT0003","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/00048674.2010.524622","article-title":"Chronic baclofen abuse and withdrawal delirium","volume":"45","author":"Nasti","year":"2011","journal-title":"Aust NZ J Psychiatry"},{"key":"2020021903593955400_CIT0004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1176\/appi.psy.46.6.503","article-title":"Delirium associated with baclofen withdrawal: a review of common presentations and management strategies","volume":"46","author":"Leo","year":"2005","journal-title":"Psychosomatics"},{"key":"2020021903593955400_CIT0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12028-014-0083-8","article-title":"Dexmedetomidine for acute baclofen withdrawal","volume":"22","author":"Morr","year":"2015","journal-title":"Neurocrit Care"},{"key":"2020021903593955400_CIT0006","first-page":"1","article-title":"Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation","volume":"0","author":"Larcoche","year":"2019","journal-title":"BMJ Support Palliat Care"},{"key":"2020021903593955400_CIT0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1941874416637404","article-title":"Oral baclofen withdrawal resulting in progressive weakness and sedation requiring intensive care admission","volume":"7","author":"Alvis","year":"2017","journal-title":"Neurohospitalist"},{"key":"2020021903593955400_CIT0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00002060-199212000-00003","article-title":"Continuous intrathecal baclofen in spinal cord spasticity: a prospective study","volume":"71","author":"Meythaler","year":"1992","journal-title":"Am J Phys Med Rehabil"},{"key":"2020021903593955400_CIT0009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3171\/jns.1993.79.4.0544","article-title":"Intrathecal baclofen down-regulates GABAB receptors in rat substantia gelatinosa","volume":"79","author":"Kroin","year":"1993","journal-title":"J Neurosurg"},{"key":"2020021903593955400_CIT0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/00207458308986578","article-title":"A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy","volume":"20","author":"Keegan","year":"1983","journal-title":"Int J Neurosci"},{"key":"2020021903593955400_CIT0011","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/15563659809028033","article-title":"Prolonged severe withdrawal symptoms after acute-on-chronic baclofen overdose","volume":"36","author":"Peng","year":"1998","journal-title":"J Toxicol Clin Toxicol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/5\/352\/32520084\/zxz332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/5\/352\/32520084\/zxz332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T04:00:00Z","timestamp":1582084800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/5\/352\/5701160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,1,13]]},"published-print":{"date-parts":[[2020,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz332","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2020,1,13]]}}}